US 12,257,253 B2
Triamterene or nolatrexed for use in the treatment of phenylketonuria
Raúl Insa Boronat, Barcelona (ES); Núria Reig Bolaño, Barcelona (ES); Aileen Ferré Ferré, Barcelona (ES); Óscar Huertas Gambin, Barcelona (ES); Santiago Esteva Gras, Barcelona (ES); Luca Signorile, Barcelona (ES); and Gal.la Pericot Mohr, Barcelona (ES)
Assigned to SOM INNOVATION BIOTECH, S.A., Barcelona (ES)
Appl. No. 17/430,060
Filed by SOM INNOVATION BIOTECH, S.A., Barcelona (ES)
PCT Filed Feb. 13, 2020, PCT No. PCT/EP2020/053714
§ 371(c)(1), (2) Date Aug. 11, 2021,
PCT Pub. No. WO2020/165318, PCT Pub. Date Aug. 20, 2020.
Claims priority of application No. 19382102 (EP), filed on Feb. 14, 2019.
Prior Publication US 2022/0133726 A1, May 5, 2022
Int. Cl. A61K 31/519 (2006.01); A61K 31/517 (2006.01); A61K 45/06 (2006.01)
CPC A61K 31/519 (2013.01) [A61K 31/517 (2013.01); A61K 45/06 (2013.01)] 7 Claims
 
1. A method of treating and/or preventing phenylketonuria (PKU) in a subject, comprising administering to said subject a therapeutically effective amount of a compound selected from the group consisting of triamterene, nolatrexed, a pharmaceutically acceptable salt of triamterene, and a pharmaceutically acceptable salt of nolatrexed.